These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 20601389

  • 21. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
    Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B, LIFE Study Investigators.
    Ann Intern Med; 2007 Sep 04; 147(5):311-9. PubMed ID: 17785486
    [Abstract] [Full Text] [Related]

  • 22. Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
    Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB.
    Circ Arrhythm Electrophysiol; 2013 Apr 04; 6(2):243-51. PubMed ID: 23403268
    [Abstract] [Full Text] [Related]

  • 23. Prognostic significance of left ventricular mass change during treatment of hypertension.
    Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B.
    JAMA; 2004 Nov 17; 292(19):2350-6. PubMed ID: 15547162
    [Abstract] [Full Text] [Related]

  • 24. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM, Wachtell K, Gerdts E, Dahlöf B, Devereux RB.
    J Hypertens; 2014 Dec 17; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
    Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Dahlöf B, LIFE Study Investigators.
    Circulation; 2006 Jan 03; 113(1):67-73. PubMed ID: 16365195
    [Abstract] [Full Text] [Related]

  • 30. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
    Ariansen I, Reims HM, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Kjeldsen SE, Dahlöf B, Wachtell K.
    Blood Press; 2012 Feb 03; 21(1):6-11. PubMed ID: 22070095
    [Abstract] [Full Text] [Related]

  • 31. QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
    Morin DP, Oikarinen L, Viitasalo M, Toivonen L, Nieminen MS, Kjeldsen SE, Dahlöf B, John M, Devereux RB, Okin PM.
    Eur Heart J; 2009 Dec 03; 30(23):2908-14. PubMed ID: 19687165
    [Abstract] [Full Text] [Related]

  • 32. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
    Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, Nieminen MS, Dahlöf B, Ibsen H, Devereux RB.
    Am J Hypertens; 2005 Nov 03; 18(11):1430-6. PubMed ID: 16280277
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
    Bang CN, Gerdts E, Aurigemma GP, Boman K, de Simone G, Dahlöf B, Køber L, Wachtell K, Devereux RB.
    Circ Cardiovasc Imaging; 2014 May 03; 7(3):422-9. PubMed ID: 24723582
    [Abstract] [Full Text] [Related]

  • 35. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
    Smebye ML, Iversen EK, Høieggen A, Flaa A, Os I, Kjeldsen SE, Olsen MH, Chattopadhyay A, Hille DA, Lyle PA, Devereux RB, Dahlöf B.
    Am J Cardiol; 2007 Sep 01; 100(5):855-9. PubMed ID: 17719333
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. In-treatment stroke volume predicts cardiovascular risk in hypertension.
    Lønnebakken MT, Gerdts E, Boman K, Wachtell K, Dahlöf B, Devereux RB.
    J Hypertens; 2011 Aug 01; 29(8):1508-14. PubMed ID: 21720264
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.